GCGR
Gene4 papersHGNC 4192NCBI Gene 2642Taxon 9606
- Human trial4
Latest
4The New England Journal of MedicineHuman trial
Survodutide reduces weight in adults with diabetes and obesity
Weekly survodutide cut body weight by up to 9.8% at 76 weeks compared to a 3.9% reduction with placebo.Weekly survodutide cut body weight by up to 9.8% at 76 weeks compared to a 3.9% reduction with placebo.
Contemporary Clinical TrialsHuman trial
Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties
The New England Journal of MedicineHuman trial
Retatrutide reduces weight and pain in adults with obesity
Mean body weight fell up to 25.0% with retatrutide versus 3.9% on placebo over 80 weeks in adults with obesity.Mean body weight fell up to 25.0% with retatrutide versus 3.9% on placebo over 80 weeks in adults with obesity.